Non-Invasive Prenatal Testing Market to Reach US$ 1,936.4 Million by 2027 - Coherent Market Insights

Non-invasive prenatal testing (NIPT) is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome.

Statistics:

The global non-invasive prenatal testing market is estimated to account for US$ 971.9 Mn in terms of value by the end of 2020.

Global Non-Invasive Prenatal Testing Market: Drivers

Launch and approval of new products is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, in November 2019, F. Hoffmann-La Roche Ltd. received approval from Health Canada for its non-invasive prenatal test, Harmony Test. The Harmony Test is designed to screen the trisomy 21 (Down syndrome) and other common fetal aneuploidies.

Global Non-Invasive Prenatal Testing Market: Opportunities

Inclusion in clinical practice guidelines is expected to offer lucrative growth opportunities for players in the global non-invasive prenatal testing market. Obtaining recommendations and inclusion of NIPT testing within clinical guidelines and frameworks is a major step in being able to educate obstetricians and increasing adoption of these tests.

Global Non Non-Invasive Prenatal Testing Market: Restraints

Abortion of pregnancy based on test results is expected to hinder growth of the global non-invasive prenatal testing market. Several cases have been identified where women have opted for abortions based on a positive screening test result due to possibility of birth with genetic defects.

Key Takeaways:

The global non-invasive prenatal testing market was estimated at US$ 971.9 Mn in 2020 and is forecast to reach a value of US$ 1,936.4 Mn by 2027 at a CAGR of 10.3% between 2020 and 2027. Launch and approval of new products is expected to propel growth of the global non-invasive prenatal testing market over the forecast period.

Panel 1 Test segment held dominant position in the global non-invasive prenatal testing market in 2019, accounting for 57.9% share in terms of value, increasing prevalence of chromosomal disorders is anticipated to propel the segment growth during the forecast period.

Market Trends

Increasing number of women smoking cigarettes is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, according to the Centers for Disease Control and Prevention, in 2018, nearly 14 of every 100 U.S. adults aged 18 years or older smoked cigarettes. Men were more likely to be current cigarette smokers than women. About 12 of every 100 adult women (12.0%) smoked cigarettes in 2018. 

Major players in the global non-invasive prenatal testing market are focused on gaining extended coverage for its products to enhance their market share. For instance, in October 2020, Natera, Inc. announced that Centene, a major healthcare insurance company, has extended coverage of the Panorama non-invasive prenatal test (NIPT) to all pregnant women, including twin pregnancies, representing 24 million additional covered lives.

Regulations

U.S.

• Prenatal testing, including new methods using cell-free fetal DNA-based NIPT, is not currently regulated by government agencies, and there is only limited regulation of the test kits and materials used in these processes.
• NIPTs are laboratory developed tests and are not approved by any regulatory authorities such as the U.S. FDA

Global Non-Invasive Prenatal Testing Market: Competitive Landscape   

Major players operating in the global non-invasive prenatal testing market include, Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom, Inc., Natera, Inc., Axia Women’s Health, Eluthia,  BillionToOne, Inc., and Quest Diagnostics Incorporated.

To know the latest trends and insights related to global Non-Invasive Prenatal Testing Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/non-invasive-prenatal-testing-nipt-market-579

Global Non-Invasive Prenatal Testing Market: Key Developments

Major players in the global non-invasive prenatal testing market are focused on launching new products to expand their product portfolio. For instance, in October 2019, BillionToOne, Inc., a diagnostics company, and Eluthia, a Europe-based genetic diagnostic tests provider, announced the launch of UNITY test, a non-invasive prenatal test, in the European region.

Segmentation

Scope of the report

• Global Non-Invasive Prenatal Testing Market, By Test Type:
  • Panel 1 Test
  • Panel 2 Test
  • Panel 3 Test
• Global Non-Invasive Prenatal Testing Market, By End User:
  • Hospitals
  • Diagnostic Laboratories
  • Maternity Centers
• Global Non-Invasive Prenatal Testing Market, By Region:
  • North America
    • By Test Type:
      • Panel 1 Test
      • Panel 2 Test
      • Panel 3 Test
    • By End User
      • Hospitals
      • Diagnostic Laboratories
      • Maternity Centers
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Test Type:
      • Panel 1 Test
      • Panel 2 Test
      • Panel 3 Test
    • By End User
      • Hospitals
      • Diagnostic Laboratories
      • Maternity Centers
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Test Type:
      • Panel 1 Test
      • Panel 2 Test
      • Panel 3 Test
    • By End User
      • Hospitals
      • Diagnostic Laboratories
      • Maternity Centers
    • By Country
      • U.K.
      • Germany
      • France
      • Spain
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Test Type:
      • Panel 1 Test
      • Panel 2 Test
      • Panel 3 Test
    • By End User
      • Hospitals
      • Diagnostic Laboratories
      • Maternity Centers
    • By Country
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Test Type:
      • Panel 1 Test
      • Panel 2 Test
      • Panel 3 Test
    • By End User
      • Hospitals
      • Diagnostic Laboratories
      • Maternity Centers
    • By Country
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • By Test Type:
      • Panel 1 Test
      • Panel 2 Test
      • Panel 3 Test
    • By End User
      • Hospitals
      • Diagnostic Laboratories
      • Maternity Centers
    • By Country
      • North Africa
      • Central Africa
      • South Africa
• Company Profiles
  • Ariosa Diagnostics, Inc. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • BGI Diagnosis Co., ltd.
  • Berry Genomics Corporation
  • Illumina, Inc.
  • LifeCodexx AG
  • Natera, Inc.
  • Sequenom, Inc.
  • Natera, Inc.
  • Axia Women’s Health
  • Eluthia
  • BillionToOne, Inc.
  • Quest Diagnostics Incorporated
•  “*” marked represents similar segmentation in other categories in the respective section.